A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Completed · Phase 1 · NCT05395481
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
At a glance
- Research payments reported, 2025
- $4.0M
- U.S. investigators named
- 15
- Sites paid
- 16
- Planned or actual enrollment
- 115
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3849891 (drug), Placebo (drug)
- Dates
- Started 2022-06-08; completion 2026-05-12
- Results posted
- Not yet
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B.
From ClinicalTrials.gov, last updated 2026-06-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $4.0M in research payments for this study in 2025 (27 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Yessica R. Sachdeva, M.D. Internal Medicine · Mesa, AZ
- Zeid K. Kayali, M.D. Internal Medicine · Rialto, CA
- Joel M. Neutel, MD Legal Medicine (non-physician) · Tustin, CA
- Simon C. Abelson, MD Internal Medicine · Miami, FL
- Eva-maria Heurich, D.O. Family Medicine · Orlando, FL
- Gilberto Perez, MD Internal Medicine · Hialeah Gardens, FL
- Edgardo J. Riverarivera, MD Emergency Medicine · Leesburg, FL
- William E. Sanchez, M.D. Internal Medicine · Hialeah, FL
- Patrick Weston, M.D. Cardiology · Bradenton, FL
- Niharika R. Samala, MD Gastroenterology · Royal Oak, MI
- David Y. Huang, MD Neurology · Chapel Hill, NC
- Grisell Ortiz Lasanta, MD Internal Medicine · San Juan, PR
- Douglas S. Denham, D.O. Family Medicine · San Antonio, TX
- David B. Huang, MD, PHD Infectious Disease · Houston, TX
- Madhavi Rudraraju, M.D. Hepatology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Advanced Pharma Cr LLC $1.3M
- Charter Research LLC $1.0M
- Floridian Clinical Research LLC $933,018
- Evolution Clinical Trials Inc $504,259
- Indiana University $75,109
- Maine Center for Cancer Medicine & $59,461
- Houston Research Institute LLC $47,529
- Institute for Liver Health LLC $32,440
- Synergy Healthcare of Tampa $31,796
- Fundacion De Investigacion De Diego $26,291
- Clinical Trials of Texas Inc $12,497
- $11,818
- Southern California Dermatology Inc $8,660
- Memorial Research Medical Clinic $6,644
- Univ of Arizona DBA Arizona Board of Regents $3,894
- Emerald Coast Neurology $2,819
- Pinnacle Clinical Research PLLC $1,705
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.